Adalimumab and methotrexate n=19
- Trial withdrawal* n=1
- Treatment failure** n=6
- Completed trial n=12

Placebo and methotrexate n=9
- Completed trial n=1
- Treatment failure** n=4
- Trial withdrawal* n=4

IMP stopped after 18 months or at time of treatment failure/trial withdrawal n=28
- Restarted Adalimumab immediately n=2
- Methotrexate monotherapy n=1
- Infliximab n=1
- Methotrexate monotherapy n=1

Adalimumab started for JIA-U flare during the extended follow-up period n=23
Median 217 days, IQR (49,386) after last dose IMP

Adalimumab stopped after SYCAMORE trial n=5
- Active JIA-U n=1
- Inactive JIA-U >2 years n=1
- Inactive JIA-U >2 years n=2
- Active JIA-U n=1

*Trial withdrawal. Suspension of methotrexate for >5 weeks - Adalimumab n=1, placebo n=1. Unable to tolerate injections - placebo n=1. Unforeseen family circumstances - placebo n=1, lack of benefit but not meeting exit criteria - placebo n=1,

**Treatment failure – At any time requirement to use concomitant medications in a manner out with predefined acceptable criteria or any of the concomitant medications not allowed - Adalimumab n=3, placebo n=1. Intermittent or continuous suspension of Adalimumab/placebo for a cumulative period longer than 4 weeks - Adalimumab n=2, placebo n=1. Sustained scores as recorded at entry grade measured over 2 consecutive readings (grades 1-2) still present after 6 months therapy - Adalimumab n=1, placebo